The Safety and Effectiveness of Cholinergic Receptor Block Therapy in the Treatment of ALS
Status:
Not yet recruiting
Trial end date:
2023-10-31
Target enrollment:
Participant gender:
Summary
Thirty cases of amyotrophic lateral sclerosis patients were recruited from the neurology
department of Ruijin Hospital, the pain department and the encephalopathy center of Luwan
Branch of Ruijin Hospital. After the informed consent was signed, they were divided into a
trial group and a control group. Each group contains 15 cases. The patients in the control
group was treated with edaravone dissolved in saline during hospitalization, while the
patients in the trial group was treated with edaravone, scopolamine, atropine and
dexmedetomidine. Both groups of subjects were treated for 7 days within 3 weeks, followed by
a buffer period of 3 weeks for observation, which was one treatment course. The total
treatment protocol contains 3 treatment courses (or 18 weeks). Patients with amyotrophic
lateral sclerosis were evaluated before treatment and 6, 12, 18, 24, 36, 48 weeks after
treatment. The observations include whether the functional scores of patients with
amyotrophic lateral sclerosis, Norris amyotrophic lateral sclerosis score, amyotrophic
lateral sclerosis self-score, forced expiratory volume in one second, partial pressure of
oxygen and maximum displacement of the hyoid were superior to those before treatment, and
whether the partial pressure of carbon dioxide was inferior to those before treatment. Study
hypothesis: Cholinergic receptor blocking therapy for amyotrophic lateral sclerosis is safe
and effective in improving motor function and delaying disease progression in patients with
amyotrophic lateral sclerosis.